The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters.

Elshout, Mari; van der Reis, Margriet I; Webers, Carroll A B; Schouten, Jan S A G

Elshout, Mari; van der Reis, Margriet I; Webers, Carroll A B; Schouten, Jan S A G.

Affiliation

Elshout M; University Eye Clinic Maastricht, Maastricht University Medical Center, PO Box 5800, 6202 AZ, Maastricht, The Netherlands, m.elshout@mumc.nl.

Graefes Arch Clin Exp Ophthalmol ; 252(12): 1911-20, 2014 Dec.

Article in En | MEDLINE | ID: mdl-24777708

Subject(s)

Angiogenesis Inhibitors/economics; Antibodies, Monoclonal, Humanized/economics; Cost-Benefit Analysis; Macular Degeneration/economics; Receptors, Vascular Endothelial Growth Factor/economics; Recombinant Fusion Proteins/economics; Aged; Aged, 80 and over; Angiogenesis Inhibitors/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Bevacizumab; Drug Costs; Female; Health Care Costs; Humans; Intravitreal Injections; Macular Degeneration/drug therapy; Male; Middle Aged; Models, Economic; Monte Carlo Method; Quality-Adjusted Life Years; Ranibizumab; Receptors, Vascular Endothelial Growth Factor/therapeutic use; Recombinant Fusion Proteins/therapeutic use; Vascular Endothelial Growth Factor A/antagonists & inhibitors; Visual Acuity/physiology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Cost-Benefit Analysis / Angiogenesis Inhibitors / Receptors, Vascular Endothelial Growth Factor / Antibodies, Monoclonal, Humanized / Macular Degeneration Type of study: Clinical_trials / Health_economic_evaluation / Prognostic_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Graefes Arch Clin Exp Ophthalmol Year: 2014 Type: Article

Fulltext

XML

PubMed Links

Search on Google